Section one: Contracting authority/entity
one.1) Name and addresses
Genomics England
One Canada Square, Canary Wharf
London
E14 5AB
Contact
Paul Nicholson
paul.nicholson@genomicsengland.co.uk
Telephone
+44 2078825030
Country
United Kingdom
Region code
UKI - London
Internet address(es)
Main address
one.4) Type of the contracting authority
Body governed by public law
one.5) Main activity
Health
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
Decision Support Service
Reference number
GeL-17/02
two.1.2) Main CPV code
- 72250000 - System and support services
two.1.3) Type of contract
Services
two.1.4) Short description
The provision of a Rare Disease Decision Support software solution for NGIS
two.1.6) Information about lots
This contract is divided into lots: No
two.1.7) Total value of the procurement (excluding VAT)
Value excluding VAT: £4,500,000
two.2) Description
two.2.3) Place of performance
NUTS codes
- UKI - London
two.2.4) Description of the procurement
In November 2018 Genomics England signed a contract with Congenica for the provision of interpretation services to support the NHS Genomic Medicine Service ("GMS") ("Decision Support Contract") which is due to expire on 30 November 2024
A contract amendment for the Rare Disease Decision Support Service contract under which Congenica will provide the services for the previously advised extension period of 6 months to 31 March 2025 and a further period of 12 months.
two.2.11) Information about options
Options: Yes
Description of options
Options to extend the term for a further 6 + 6 months.
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
Section four. Procedure
four.1) Description
four.1.1) Type of procedure
Award of a contract without prior publication of a call for competition in the cases listed below
- The procurement falls outside the scope of application of the regulations
Explanation:
Genomics England takes the view that Regulation 72 (1) (b) applies to the variation to the Decision Support Contract because additional services from Congenica have become necessary but were not included in the original procurement of this contract but a change of contractor cannot be made at this time due to the bespoke technical specification of the product and it would also cause significant duplication of cost for Genomics England. The value of the variation is under 50% of the value of the Decision Support Contract.
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: Yes
Section five. Award of contract/concession
Contract No
GeL-17/02
Title
Decision Support Services
A contract/lot is awarded: Yes
five.2) Award of contract/concession
five.2.1) Date of conclusion of the contract
20 November 2024
five.2.2) Information about tenders
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor/concessionaire
Congenica
Wellcome Genome Campus
Cambridge
CB10 1DR
Country
United Kingdom
NUTS code
- UKH12 - Cambridgeshire CC
The contractor/concessionaire is an SME
Yes
five.2.4) Information on value of contract/lot/concession (excluding VAT)
Initial estimated total value of the contract/lot/concession: £4,500,000
Total value of the contract/lot/concession: £4,500,000
five.2.5) Information about subcontracting
The contract/lot/concession is likely to be subcontracted
Section six. Complementary information
six.3) Additional information
Genomics England will on 1 December 2024 enter into a contract amendment for the Decision Support Service Contract under which Congenica will provide the services for the previously advised extension period of 6 months to 31 March 2025 and a further period of 12 months with an option to extend for a further 6 + 6 months.
Genomics England takes the view that Regulation 72 (1) (b) applies to the variation to the Decision Support Contract because additional services from Congenica have become necessary but were not included in the original procurement of this contract but a change of contractor cannot be made at this time due to the bespoke technical specification of the product and it would also cause significant duplication of cost for Genomics England. The value of the variation is under 50% of the value of the Decision Support Contract.
NHS England has confirmed that a functioning decision support system for rare disease is essential to the success of the GMS for rare disease and no hiatus in these services is possible. Genomics England has very specific requirements for decision support as any product needs to fit in with its internal National Genomics Informatics System (NGIS) pipeline and no off the shelf product is available or viable without significant development. Given the background to Congenica development, an immediate termination would not only have led to a hiatus in service but would cause substantial inconvenience and duplication of costs should a new decision support provider be brought in.
Genomics England are in the process of developing a replacement solution.
six.4) Procedures for review
six.4.1) Review body
High Court
London
Country
United Kingdom